Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors
- PMID: 3084539
- DOI: 10.1210/jcem-62-6-1296
Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors
Abstract
To examine the long term effectiveness of transsphenoidal microsurgery for patients with PRL-secreting pituitary tumors, we studied 54 women at yearly intervals after transsphenoidal surgery. Five years after surgery, 19 women (35%) had normal serum PRL concentrations, and 23 (43%) had persistent hyperprolactinemia. Hyperprolactinemia recurred in 12 of 31 patients (39%) who had normal PRL concentration 6 weeks after surgery. None of the patients with recurrent hyperprolactinemia had radiographic evidence of tumor regrowth, and only 3 of 12 had amenorrhea. A serum PRL level below 6 ng/ml 6 weeks after surgery occurred more frequently in cured patients than in those who had a recurrence. PRL responses to TRH were normal in cured patients 1 and 5 yr after surgery and abnormal in those who had recurrent hyperprolactinemia. The PRL responses to chlorpromazine- and insulin-induced hypoglycemia were blunted in patients with normal as well as elevated PRL levels. Patients with recurrent, as well as those with persistent, hyperprolactinemia had no nocturnal rise in serum PRL 5 yr after surgery. The 39% recurrence rate of hyperprolactinemia and persistent abnormalities in pituitary-hypothalamic regulation of PRL secretion after transsphenoidal surgery raise important questions about the choice of primary therapy for patients with PRL-secreting tumors.
Similar articles
-
Serum prolactin response to thyrotropin-releasing hormone and metoclopramide in patients with prolactin-secreting tumors before and after transsphenoidal surgery.J Clin Endocrinol Metab. 1978 Nov;47(5):1148-51. doi: 10.1210/jcem-47-5-1148. J Clin Endocrinol Metab. 1978. PMID: 122421
-
Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.J Clin Endocrinol Metab. 2002 Jul;87(7):3180-6. doi: 10.1210/jcem.87.7.8645. J Clin Endocrinol Metab. 2002. PMID: 12107221
-
Prolactin secretion in acromegalic patients before and after selective adenomectomy.J Clin Endocrinol Metab. 1985 Jul;61(1):104-9. doi: 10.1210/jcem-61-1-104. J Clin Endocrinol Metab. 1985. PMID: 3923026
-
Control of prolactin secretion.Klin Wochenschr. 1990 Dec 4;68(23):1157-67. doi: 10.1007/BF01815271. Klin Wochenschr. 1990. PMID: 2126309 Review.
-
Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology.Ann Endocrinol (Paris). 2007 Feb;68(1):58-64. doi: 10.1016/j.ando.2006.11.001. Epub 2007 Feb 20. Ann Endocrinol (Paris). 2007. PMID: 17316545 Review. No abstract available.
Cited by
-
Advances in diagnosing and managing pituitary adenomas.West J Med. 1995 Apr;162(4):371-3. West J Med. 1995. PMID: 7747512 Free PMC article. No abstract available.
-
Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.Chin Neurosurg J. 2022 Apr 8;8(1):9. doi: 10.1186/s41016-022-00277-1. Chin Neurosurg J. 2022. PMID: 35395837 Free PMC article.
-
Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Pituitary. 2011 Sep;14(3):222-30. doi: 10.1007/s11102-010-0283-y. Pituitary. 2011. PMID: 21170594 Free PMC article.
-
Hyperprolactinemia: neuroendocrine and diagnostic aspects.J Endocrinol Invest. 1989 Oct;12(9):653-68. doi: 10.1007/BF03350030. J Endocrinol Invest. 1989. PMID: 2685096 Review. No abstract available.
-
The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.Pituitary. 2022 Jun;25(3):508-519. doi: 10.1007/s11102-022-01221-3. Epub 2022 Apr 25. Pituitary. 2022. PMID: 35467273
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical